Skip to main content

Home/ Dr. Goodyear/ Group items tagged difference

Rss Feed Group items tagged

Nathan Goodyear

Glucocorticoids and 11beta-hydroxysteroid... [Minerva Endocrinol. 2007] - PubMed - NCBI - 0 views

  •  
    Dysregulation of 11-betaHSD1 plays significant role in metabolic syndrome.  Decreased 11-betaHSD activity is found in the liver and increased 11-betaHSD1  is found in peripheral fat.  Take home: 11-betaHSD1 activity and cortisol metabolism differs in different tissue
Nathan Goodyear

Active placebos versus antidepressants for depression - The Cochrane Library - Moncrief... - 0 views

  •  
    cochrane review of 9 studies involving 751 patients, shows little difference between antidepressants and "active placebos".  The two groups both improved mood, but there was very little difference between the 2.  Take home: "...the effects of antidepressants my be generally overestimated..."
Nathan Goodyear

Gastrointestinal Symptoms in a sample of children with Pervasive Developmental Disorders - 0 views

  •  
    This study didn't find major differences between children with/without GI symptoms in those with PDD. But some differences were identified: more anxiety, more listlessness, and more refractory to medical therapy in children with PDD and GI symptoms.
Nathan Goodyear

Boswellic acids: A leukotriene inhibitor also effective through topical application in ... - 0 views

  •  
    Boswellic acid shown to have systemic anti-inflammatory effects through topical application.  This study only looked at Boswellia Serrata and it's triterpenes.  The different Boswellia have different levels of AKBA, BA, and BKA.
Nathan Goodyear

Human biological monitoring of suspected endocrine-disrupting compounds Fanib... - 0 views

  •  
    Review of xenoestrogens and techniques for evaluation.  Brief discussion of the different EDCs is included, but the majority of the study is to evaluate the different testing techniques.
Nathan Goodyear

Significance of oestrogens in male (p... [Ann Endocrinol (Paris). 2003] - PubMed - NCBI - 0 views

  •  
    Just the abstract available, but estrogens have different effects in the male physiology--no surprise.  But, the different ages of the men appear to effect the estrogenic effects as well.  This would imply that the microenvironments change the way the Testosterone is used by the body.
Nathan Goodyear

JAMA Network | JAMA | Circulating Estradiol and Mortality in Men With Systolic Chronic ... - 0 views

  •  
    Study of 500 men with CHF and reduced LVEF found that estradiol has a "U" shaped relationship to prognosis.  A low and high estradiol levels are associated with increased poor prognosis.  Other biomarkers in these 2 groups were different, suggesting different physiologic mechanisms.
Nathan Goodyear

The dialectic role of progesterone - 0 views

  •  
    Just the abstract available here.  Article states the complexity of hormones found in hormone metabolism.  I love the authors quote, "As steroid hormones are known to be converted to many other steroids occupying different receptors and thereby exerting various different effects..."  Doesn't fit into the "know your numbers" marketing deception does it?
wheelchairindia9

Chair For Cerebral Palsy Child - 0 views

  •  
    Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks. Cerebral palsy causes problems with muscle tone, movement, balance and/or coordination. Symptoms and effects range from mild to severe. In some infants, problems are evident soon after birth. In others, diagnosis comes in later infancy or toddlerhood. Cerebral Palsy Wheelchair Description: The model designed for cerebral palsy child only. Ultra light weight aluminium alloy frame. Seat Width 38 cms (15"). Net Weight: 18.5 kgs. Epoxy powder coated frame. Detachable arm rest & foot rest provided. Elevated and swinging foot rest. Elevated foot rest provided to elevate leg angle. Height adjustable and detachable head rest. Hydraulic reclining high back for a comfortable posture. Hydraulic adjustable seat angle. Detachable back and seat pad. Extra cushion upholstery provided to under arm, head & calg Foldable. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cloth look like water proof upholstery. Anti wheels for better safety and stability. Extra cushion upholstery provided to under arm, head & leg Folding action. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cerebral Palsy Wheelchair Recline system: Recline system provides kids with the most comfortable resting environment. It also allows stretching abdomin
wheelchairindia9

KM 7501 Wheelchair - 0 views

  •  
    Ergonomic Wheelchair often spend a lot of time leaning on armrests or a table exactly because they are not being supported with good posture in their chairs. This is a matter of seat angle and back angle, adjusting them according to body shape and degree of upper body balance. Poor seating makes slump, trying to get stable. The optimal posture is more upright, allowing spine to support. Ergonomic chairs are designed to confirm to a person's physical dimensions, allowing them to sit naturally and comfortably for long periods of time, while reducing the risk of pressure ulcers. Ergonomic system (Intelligent s-shaped ergonomic seating) provides efficient pressure relief by spreading weight over a greater area, at the same time provides stabilization and reduced sliding. With their lightweight frames and seats designed to reduce or prevent pressure points, ergonomic wheelchairs provide a comfortable option for mobility impaired users who have the upper body strength to propel themselves, or a caregiver strong enough to do so. Karma S Ergo 115 Wheelchair: This model features our S-Shape Seating System and is our number one best seller for many reasons. At a mere 11.3 kg in weight with detachable foot rest and many features such as removable machine washable and dry-able cushions treated by AEIGIS treated anti-microbial coated seating system. Karma S-Ergo 115 Wheelchair Features: Ergonomic Handrims & S-Shape Ergonomic Seating System Fixed armrest w/ wider concave armpads Swing In & Away Footrests Backrest Pouch attached to the upholstery 24" flat free polyurethane tires, high tread, flat free wheels Seat width: 16"x17" or 18"x17" or 20"x 17" Silver 1/4" Aegis Anti-Bacterial Upholstery, washable Folding backrest / folding seat for easy traveling "Tube-in Center" foot-plate, assures better side leg support High strength, starting weight at only 11.3 kg. (w/o footrests) 7×1" Polyurethane front casters Upholstery: Black breathable mesh bottom & t
wheelchairindia9

Karma 8020 Wheelchair - 0 views

  •  
    Heavy duty wheelchair can either be manually-operated or motorized, each with its own pros and cons. A manual heavy-duty wheelchair gives full control of motion to the user, but the added weight from the reinforcements makes pushing or propelling the wheelchair much harder than normal. A motorized heavy duty wheelchair offers a solution to this dilemma, but is often more expensive and harder to maintain than a manual wheelchair. Some designs offer a combination of both, with a small motor assisting those pushing the wheelchair. The proper choice between types of Heavy Duty wheelchair depends largely on the user's expected level of activity. Heavy duty wheelchairs typically have larger seats than conventional wheelchairs. The frames of these wheelchairs can be made from several different reinforced metals, although a titanium wheelchair is often the most popular choice. The wheels themselves are made of thicker rubber than normal, preventing any possible failure due to the greater amount of weight supported. Most makes of heavy duty wheelchairs fold like regular wheelchairs, making storage relatively easy despite the wheelchair increased size. Heavy Duty Wheelchair specialy design for disabled and handicapped persons. They are two types of Heavy Duty Wheelchair for handicapped and disability product like- Karma 8020 X Heavy Duty Wheelchair Karma 8520 Heavy Duty Wheelchair Karma 8020 X Heavy Duty Wheelchair: It comes with detachable swing away footrests. The wheel chair has flip-back armrests. It comes with centre of gravity adjustment. The wheel chair has wide profile casters. Seat Size 20'' inch & 22'' inch Total Weight 17 K.G. Designed for maximum strength & weight capacity for people over 250 lbs. These end to be heavier and wider. This heavy duty bariatric wheelchair has seat dimensions of 24 inches wide by 18 inches deep to accommodate a weight capacity of up to 400 lbs. This wheelchair is dual axle, which means that the floor to seat heigh
wheelchairindia9

Karman Ergo Lite S-2501 Wheelchair - 0 views

  •  
    Karma Ergo Lite 2501 Wheelchair The extremely lightweight Ergo Lite 2501 Transport Wheelchair weighs only 8.16 kg. and features an ergonomically-designed seat and backrest, making it one of the most comfortable transport chairs on the market. The folding seat and backrest make the S-Ergo ideal for storage or travel, and the built in AEGIS anti-bacterial cushion provides added comfort and support. Despite its light weight, the S-Ergo features a 115 kg. weight capacity along with large, 14" flat-free polyurethane rear tires. Karma Ergo Lite 2501 Wheelchair Features Lightest transporter on the market! Patented S-Style Ergonomic Seat Frame 6061 T-6 Aircraft-grade Aluminum Only 18 lb . (w/ footrests) Built in Silver Aegis Anti-bacterial Cushion Fixed Armrests w/Concaved Armpads Pocket Behind Backrest & Small Carry Pouch on Each Armrest 6" x 1" Polyurethane Front Casters 16" x 17" or 18" x 17" Seat Width S-Style Ergonomic Seat 14" Rear Polyurethane, High Tread, Flat Free Wheels 3-Stage handle brake: allows light to firm grip for lock Folding Backrest/ Folding Seat for Transporting in Vehicle or Travel Fixed Footrests w/ Extra Wide Footplates Frame Color: Pearl Silver Weight Capacity of 100 kg Ergonomic Transporter w/ handle brakes Karma Ergo Lite 2501 Wheelchair Measurements Seat Width 16 inch., 18 inch. Seat Depth 17 inch. Armrest Height 8 inch. Seat Height 19 inch. Back Height 17 inch. Overall Height 36 inch. Overall Open Width 23 inch., 25 inch. Folded Width 12 inch. Overall Length 39 inch. Weight Without Riggings 8 kg. Weight Cap 100 kg. Shipping Dimensions 35" L x 30" H x 12" W
Nathan Goodyear

Comparative Rates of Androgen Production and Metabolism in Caucasian and Chinese Subjects - 0 views

  •  
    In conclusion, dietary or environmental factors, and not a diminution of 5α-reductase, appear to be responsible for differences in androgen metabolism between Caucasians living in the United States and Chinese living in China.  Powerful conclusion that environmental factors play a major role in the difference in Testosterone function between caucasian men in Western countries vs. Chinese men in Eastern countries
Nathan Goodyear

Resistance training increases SHBG in overweight/obese, young men - 0 views

  •  
    12 week study of obese  men in resistance training program finds increase in SHBG and resultant decrease in free Androgen index.  FAI is as a calculation of free Testosterone.  This is different in the studies in lean men which shows an increase in Testosterone. Here a different underlying metabolism is the result
Nathan Goodyear

Intravenous Fluid Use in Athletes - 0 views

  • Treatment of exercise-associated hyponatremia with hypertonic IV infusion to correct plasma sodium levels is also a standard and accepted use of IV fluid infusions
  • athletes who present for medical care with hypernatremia who cannot tolerate oral fluids can benefit from IV fluids
  • Vaporization of sweat accounts for 80% of heat loss in hot, dry atmospheric conditions. This mechanism of water loss is the major contributor for exercise-associated dehydration
  • ...30 more annotations...
  • The rate of water loss can be quantified through measurement of sweat rate
  • Pre- and postexercise body weight measurements are the most common means to estimate overall water loss but are condition specific
  • It appears that 1% to 2% body weight loss is well tolerated by the exercising athlete
  • Dehydration, defined as greater than 2% loss of body weight, can negatively affect performance
  • In highly trained endurance athletes, plasma volume and sodium serum concentration were preserved despite a 5% body weight loss
  • In Ironman triathletes, dehydration to 5% body weight loss did not correlate with occurrence of medical complications
  • hydration should begin hours prior to exercise, especially if known deficits are present, and fluids should be consumed at a slow, steady rate, with 5 to 7 mL/kg taken 4 hours prior to exercise
  • Sodium concentration did not produce significant changes in the rate of absorption but was primarily dependent on carbohydrate concentration
  • Replacing 150% of body weight loss over 60 minutes has been tolerated without complications
  • IV treatment of severe dehydration (>7% body weight loss), exertional heat illness, nausea, emesis, or diarrhea, and in those who cannot ingest oral fluids for other reasons, is clinically indicated
  • A recent survey of the National Football League teams revealed that 75% (24 of 32) of the teams utilized IV infusion of fluids for prehydration in at least some otherwise healthy individuals
  • In the National Football League, an average of 1.5 L of normal saline was administered approximately 2.5 hours prior to competition
  • after 2 hours of exercise, the rectal temperature was 0.6° higher in the group not receiving IV infusion. Also, stroke volume and cardiac output were 11% to 16% lower in the control group versus the IV infusion group.
  • Recent evidence suggests the etiology of EAMC is related to muscle fatigue and neuronal excitability
  • no correlation between hydration status or electrolyte concentrations with EAMC
  • there may be a subset of muscle cramping that is associated with a loss of both body fluid and sodium
  • Glycerol is the primary agent for oral hyperhydration
  • elevation of plasma volume by 200 to 300 mL via dextran infusion resulted in 15% increase in stroke volume, 4% increase in VO2 max, and an increase in the exercise time to fatigue
  • Neither the tonicity nor mode of hydration resulted in improved speed of rehydration, greater fluid retention, or improved performance
  • There are beneficial anecdotal reports of EAMC treatment in elite and professional-level athletes with IV hydration during the course of an event
  • Plasma volume was better restored during rehydration with IV fluids at preexercise and 5 minutes of exercise. At 15 minutes, there was no difference between IV and oral rehydration
  • More rapid restoration of plasma volume was accomplished in the IV treatment group with no advantages over oral rehydration in physiological strain, heat tolerance, ratings of perceived effort, or thermal sensations
  • No difference was found in exercise time to exhaustion. IV and oral rehydration methods were equally effective. Heart rates were statistically higher in the oral rehydration group through 75 minutes of exercise, and there were higher increases in norepinephrine plasma concentrations
  • No significant differences between the groups were found for time to recovery, number of days with pain, number of days with stiffness, sleep disturbance, fatigue, rectal temperature, and loss of appetite
  • The current data suggest that IV rehydration is faster than oral
  • There may be physiological benefits of decreased heart rate and norepinephrine in athletes rehydrated via IV route
  • Postexercise blood 1 hour and 24 hours showed no differences in circulating myoglobin or creatine kinase
  • The use of IV fluid may be beneficial for a subset of fluid sensitive athletes
  • this should be reserved for high-level athletes with strong histories of symptoms in well-monitored settings.
  • Volume expanders may also be beneficial for some athletes
  •  
    to be read
Nathan Goodyear

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1332190/pdf/brjsmed00019-0063.pdf - 0 views

  •  
    study finds IV hydration with glucose and larger volume did not recover as well as those with 100 ml  of IV fluids.  This conclusion is incomplete as the time differences between the 2 groups was significant--group 2 (2.5 L fluid group) finished much faster and studies have shown that these endurance athletes are more prone to dehydration, more significant weight loss, adverse effects from the event.  This likely explains the difference between the 2 groups.
Nathan Goodyear

N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis o... - 0 views

  • compared effects of NAC with placebo or metformin in women with PCOS
  • NAC significantly improved rates of live births and spontaneous ovulation compared to placebo in women with PCOS
  • we found no evidence of effects of NAC on improving menstrual regularity, acne, hirsutism, BMI, fasting insulin, fasting glucose, or HOMA-IR
  • ...3 more annotations...
  • NAC was not associated with greater benefits to metformin for improving pregnancy rate, spontaneous ovulations, and menstrual regularity
  • Metformin also improved the BMI, total testosterone, insulin level, and lipid levels compared to NAC
  • All the studies were of short duration (three months)
  •  
    Data review finds NAC improves pregnancy rates and ovulation rates in women with PCOS against placebo.  Meta-analysis revealed limited studies on the topic.  When compared to metformin, there was no difference found.  Though, one wonders if attacking insulin resistance through proper diet and additional neutraceutical approach would negate that.  The reason?  NAC and metformin are working in different biochemical pathways.  The authors here seem to not realize this. It appears that they think NAC and metormin are both working in the same manner, but they don't.  The fact that there is still benefit found compared to placebo, despited the authors lack of understanding of what NAC is and does is a positive.
Nathan Goodyear

Axillary dissection versus no axillary dissection in patients with breast cancer and se... - 0 views

  •  
    study finds no disease free survival difference in those women with breast cancer and sentinel node metastasis for axillary lymph node dissection versus no disecction; no difference in overall survival at 10 years also observed.
fnfdoc

Cancer Chemotherapy Via Drugs | Your Health Our Priority - 0 views

  •  
    How chemotherapy takes place? Depending on type of cancer and period of cancer, it stops cancer cells ability of damage and more to divide. Oftenly drugs are used and different for different person. This is systematic therapy also affect your entire body.
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  •  
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
‹ Previous 21 - 40 of 436 Next › Last »
Showing 20 items per page